Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial)

BACKGROUND: Major depressive disorder is a common debilitating illness that is the second leading contributor to the global burden of disease. Unfortunately, about 30 % of patients do not respond to adequate trials of antidepressants and/or psychotherapies. About 45–60 % of such treatment-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Finnegan, Martha, Ryan, Karen, Shanahan, Enda, Harkin, Andrew, Daly, Leslie, McLoughlin, Declan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153900/
https://www.ncbi.nlm.nih.gov/pubmed/27965856
http://dx.doi.org/10.1186/s40814-016-0080-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153900/
https://www.ncbi.nlm.nih.gov/pubmed/27965856
http://dx.doi.org/10.1186/s40814-016-0080-0

Ejemplares similares